Published in J Neurosci on November 19, 2008
Molecular interplay between mammalian target of rapamycin (mTOR), amyloid-beta, and Tau: effects on cognitive impairments. J Biol Chem (2010) 3.16
Beneficial effect of human anti-amyloid-beta active immunization on neurite morphology and tau pathology. Brain (2010) 2.33
Inducing autophagy by rapamycin before, but not after, the formation of plaques and tangles ameliorates cognitive deficits. PLoS One (2011) 1.62
Methylene blue reduces aβ levels and rescues early cognitive deficit by increasing proteasome activity. Brain Pathol (2011) 1.46
CBP gene transfer increases BDNF levels and ameliorates learning and memory deficits in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A (2010) 1.37
5-Lipoxygenase gene transfer worsens memory, amyloid, and tau brain pathologies in a mouse model of Alzheimer disease. Ann Neurol (2012) 1.31
Ubiquitin/proteasome pathway impairment in neurodegeneration: therapeutic implications. Apoptosis (2010) 1.31
mTOR regulates tau phosphorylation and degradation: implications for Alzheimer's disease and other tauopathies. Aging Cell (2013) 1.24
Modeling familial Danish dementia in mice supports the concept of the amyloid hypothesis of Alzheimer's disease. Proc Natl Acad Sci U S A (2010) 1.21
Identification of dihydropyridines that reduce cellular tau levels. Chem Commun (Camb) (2010) 1.17
Naturally secreted amyloid-beta increases mammalian target of rapamycin (mTOR) activity via a PRAS40-mediated mechanism. J Biol Chem (2011) 1.12
The β-secretase-derived C-terminal fragment of βAPP, C99, but not Aβ, is a key contributor to early intraneuronal lesions in triple-transgenic mouse hippocampus. J Neurosci (2012) 1.11
Soluble aβ promotes wild-type tau pathology in vivo. J Neurosci (2012) 1.06
Nonhuman primate models of Alzheimer-like cerebral proteopathy. Curr Pharm Des (2012) 1.06
The role of mTOR signaling in Alzheimer disease. Front Biosci (Schol Ed) (2012) 1.05
Defective lysosomal proteolysis and axonal transport are early pathogenic events that worsen with age leading to increased APP metabolism and synaptic Abeta in transgenic APP/PS1 hippocampus. Mol Neurodegener (2012) 1.03
Mechanisms of action of non-steroidal anti-inflammatory drugs for the prevention of Alzheimer's disease. CNS Neurol Disord Drug Targets (2010) 0.95
Mammalian target of rapamycin hyperactivity mediates the detrimental effects of a high sucrose diet on Alzheimer's disease pathology. Neurobiol Aging (2013) 0.94
Cyclooxygenase-1 inhibition reduces amyloid pathology and improves memory deficits in a mouse model of Alzheimer's disease. J Neurochem (2012) 0.91
Age-dependent changes in TDP-43 levels in a mouse model of Alzheimer disease are linked to Aβ oligomers accumulation. Mol Neurodegener (2010) 0.90
Amyloid beta and the longest-lived rodent: the naked mole-rat as a model for natural protection from Alzheimer's disease. Neurobiol Aging (2013) 0.89
Homocysteine exacerbates β-amyloid pathology, tau pathology, and cognitive deficit in a mouse model of Alzheimer disease with plaques and tangles. Ann Neurol (2014) 0.89
Transgenic mouse models of Alzheimer disease: developing a better model as a tool for therapeutic interventions. Curr Pharm Des (2012) 0.88
The 12-15-lipoxygenase is a modulator of Alzheimer's-related tau pathology in vivo. Aging Cell (2013) 0.87
5-Lipoxygenase pharmacological blockade decreases tau phosphorylation in vivo: involvement of the cyclin-dependent kinase-5. Neurobiol Aging (2013) 0.86
Reducing Ribosomal Protein S6 Kinase 1 Expression Improves Spatial Memory and Synaptic Plasticity in a Mouse Model of Alzheimer's Disease. J Neurosci (2015) 0.85
Intraneuronal aggregation of the β-CTF fragment of APP (C99) induces Aβ-independent lysosomal-autophagic pathology. Acta Neuropathol (2016) 0.82
Administration of a selective β2 adrenergic receptor antagonist exacerbates neuropathology and cognitive deficits in a mouse model of Alzheimer's disease. Neurobiol Aging (2014) 0.82
FLZ alleviates the memory deficits in transgenic mouse model of Alzheimer's disease via decreasing beta-amyloid production and tau hyperphosphorylation. PLoS One (2013) 0.81
The neuritic plaque facilitates pathological conversion of tau in an Alzheimer's disease mouse model. Nat Commun (2016) 0.81
Exploiting the diversity of the heat-shock protein family for primary and secondary tauopathy therapeutics. Curr Neuropharmacol (2011) 0.81
Alzheimer's disease and neuronal network activity. Neuromolecular Med (2009) 0.80
Pharmacologic blockade of 12/15-lipoxygenase ameliorates memory deficits, Aβ and tau neuropathology in the triple-transgenic mice. Mol Psychiatry (2015) 0.79
PINCH in the cellular stress response to tau-hyperphosphorylation. PLoS One (2013) 0.78
Animal models for Alzheimer's disease and frontotemporal dementia: a perspective. ASN Neuro (2009) 0.78
Drug targets from genetics: α-synuclein. CNS Neurol Disord Drug Targets (2011) 0.78
Genetic suppression of β2-adrenergic receptors ameliorates tau pathology in a mouse model of tauopathies. Hum Mol Genet (2014) 0.77
CHIP stabilizes amyloid precursor protein via proteasomal degradation and p53-mediated trans-repression of β-secretase. Aging Cell (2015) 0.77
The multiple mechanisms of amyloid deposition: the role of parkin. Prion (2009) 0.77
β-Secretase 1's Targeting Reduces Hyperphosphorilated Tau, Implying Autophagy Actors in 3xTg-AD Mice. Front Cell Neurosci (2016) 0.76
The Proteasome and Oxidative Stress in Alzheimer's Disease. Antioxid Redox Signal (2016) 0.75
FcγRIIb-SHIP2 axis links Aβ to tau pathology by disrupting phosphoinositide metabolism in Alzheimer's disease model. Elife (2016) 0.75
Dyrk1 inhibition improves Alzheimer's disease-like pathology. Aging Cell (2017) 0.75
Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron (2003) 14.03
Alzheimer's disease. N Engl J Med (2010) 13.13
A microfluidic culture platform for CNS axonal injury, regeneration and transport. Nat Methods (2005) 7.62
Intraneuronal Abeta causes the onset of early Alzheimer's disease-related cognitive deficits in transgenic mice. Neuron (2005) 6.20
Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron (2004) 5.52
Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer's disease. Neurobiol Aging (2003) 3.83
Lipopolysaccharide-induced inflammation exacerbates tau pathology by a cyclin-dependent kinase 5-mediated pathway in a transgenic model of Alzheimer's disease. J Neurosci (2005) 3.18
Neural stem cells improve cognition via BDNF in a transgenic model of Alzheimer disease. Proc Natl Acad Sci U S A (2009) 2.96
Caspase-cleavage of tau is an early event in Alzheimer disease tangle pathology. J Clin Invest (2004) 2.80
Microglial Cx3cr1 knockout prevents neuron loss in a mouse model of Alzheimer's disease. Nat Neurosci (2010) 2.79
Temporal profile of amyloid-beta (Abeta) oligomerization in an in vivo model of Alzheimer disease. A link between Abeta and tau pathology. J Biol Chem (2005) 2.56
Glucocorticoids increase amyloid-beta and tau pathology in a mouse model of Alzheimer's disease. J Neurosci (2006) 2.45
Reduction of soluble Abeta and tau, but not soluble Abeta alone, ameliorates cognitive decline in transgenic mice with plaques and tangles. J Biol Chem (2006) 2.33
Enhanced ryanodine receptor recruitment contributes to Ca2+ disruptions in young, adult, and aged Alzheimer's disease mice. J Neurosci (2006) 2.32
Gene expression changes in the course of normal brain aging are sexually dimorphic. Proc Natl Acad Sci U S A (2008) 2.29
Positive association between altitude and suicide in 2584 U.S. counties. High Alt Med Biol (2011) 2.28
IKK phosphorylates Huntingtin and targets it for degradation by the proteasome and lysosome. J Cell Biol (2009) 2.16
Synergistic Interactions between Abeta, tau, and alpha-synuclein: acceleration of neuropathology and cognitive decline. J Neurosci (2010) 2.12
M1 receptors play a central role in modulating AD-like pathology in transgenic mice. Neuron (2006) 2.07
Adjuvant-dependent modulation of Th1 and Th2 responses to immunization with beta-amyloid. Int Immunol (2003) 2.02
Progesterone and estrogen regulate Alzheimer-like neuropathology in female 3xTg-AD mice. J Neurosci (2007) 2.00
A physiologic signaling role for the gamma -secretase-derived intracellular fragment of APP. Proc Natl Acad Sci U S A (2002) 1.97
Dysregulated IP3 signaling in cortical neurons of knock-in mice expressing an Alzheimer's-linked mutation in presenilin1 results in exaggerated Ca2+ signals and altered membrane excitability. J Neurosci (2004) 1.92
Patterned cell culture inside microfluidic devices. Lab Chip (2004) 1.89
Nicotinamide restores cognition in Alzheimer's disease transgenic mice via a mechanism involving sirtuin inhibition and selective reduction of Thr231-phosphotau. J Neurosci (2008) 1.88
SERCA pump activity is physiologically regulated by presenilin and regulates amyloid beta production. J Cell Biol (2008) 1.84
Linking calcium to Abeta and Alzheimer's disease. Neuron (2008) 1.82
Microfluidic Multicompartment Device for Neuroscience Research. Langmuir (2003) 1.72
Inflammation induces tau pathology in inclusion body myositis model via glycogen synthase kinase-3beta. Ann Neurol (2008) 1.71
Age- and region-dependent alterations in Abeta-degrading enzymes: implications for Abeta-induced disorders. Neurobiol Aging (2005) 1.68
A dynamic relationship between intracellular and extracellular pools of Abeta. Am J Pathol (2006) 1.66
Treatment with a C5aR antagonist decreases pathology and enhances behavioral performance in murine models of Alzheimer's disease. J Immunol (2009) 1.66
Early correlation of microglial activation with enhanced tumor necrosis factor-alpha and monocyte chemoattractant protein-1 expression specifically within the entorhinal cortex of triple transgenic Alzheimer's disease mice. J Neuroinflammation (2005) 1.64
Impaired adult neurogenesis in the dentate gyrus of a triple transgenic mouse model of Alzheimer's disease. PLoS One (2008) 1.62
Inhibition of soluble TNF signaling in a mouse model of Alzheimer's disease prevents pre-plaque amyloid-associated neuropathology. Neurobiol Dis (2009) 1.60
Calpain inhibitor A-705253 mitigates Alzheimer's disease-like pathology and cognitive decline in aged 3xTgAD mice. Am J Pathol (2012) 1.60
Abeta inhibits the proteasome and enhances amyloid and tau accumulation. Neurobiol Aging (2007) 1.58
Prototype Alzheimer's disease vaccine using the immunodominant B cell epitope from beta-amyloid and promiscuous T cell epitope pan HLA DR-binding peptide. J Immunol (2005) 1.56
Ibuprofen reduces Abeta, hyperphosphorylated tau and memory deficits in Alzheimer mice. Brain Res (2008) 1.56
Chronic neuron-specific tumor necrosis factor-alpha expression enhances the local inflammatory environment ultimately leading to neuronal death in 3xTg-AD mice. Am J Pathol (2008) 1.55
Enhanced caffeine-induced Ca2+ release in the 3xTg-AD mouse model of Alzheimer's disease. J Neurochem (2005) 1.52
Calcium dysregulation in Alzheimer's disease: recent advances gained from genetically modified animals. Cell Calcium (2005) 1.52
Females exhibit more extensive amyloid, but not tau, pathology in an Alzheimer transgenic model. Brain Res (2008) 1.51
Chronic nicotine administration exacerbates tau pathology in a transgenic model of Alzheimer's disease. Proc Natl Acad Sci U S A (2005) 1.51
Dietary docosahexaenoic acid and docosapentaenoic acid ameliorate amyloid-beta and tau pathology via a mechanism involving presenilin 1 levels. J Neurosci (2007) 1.47
Controlled cortical impact traumatic brain injury in 3xTg-AD mice causes acute intra-axonal amyloid-β accumulation and independently accelerates the development of tau abnormalities. J Neurosci (2011) 1.47
Methylene blue reduces aβ levels and rescues early cognitive deficit by increasing proteasome activity. Brain Pathol (2011) 1.46
Neural stem cells improve memory in an inducible mouse model of neuronal loss. J Neurosci (2007) 1.46
Lifelong rapamycin administration ameliorates age-dependent cognitive deficits by reducing IL-1β and enhancing NMDA signaling. Aging Cell (2012) 1.43
Reducing AD-like pathology in 3xTg-AD mouse model by DNA epitope vaccine - a novel immunotherapeutic strategy. PLoS One (2008) 1.42
Exercise alters the immune profile in Tg2576 Alzheimer mice toward a response coincident with improved cognitive performance and decreased amyloid. J Neuroinflammation (2008) 1.38
Blocking IL-1 signaling rescues cognition, attenuates tau pathology, and restores neuronal β-catenin pathway function in an Alzheimer's disease model. J Immunol (2011) 1.36
Relevance of transgenic mouse models to human Alzheimer disease. J Biol Chem (2008) 1.36
Enteropathogenic Escherichia coli use redundant tyrosine kinases to form actin pedestals. Mol Biol Cell (2004) 1.32
Sustained interleukin-1β overexpression exacerbates tau pathology despite reduced amyloid burden in an Alzheimer's mouse model. J Neurosci (2013) 1.32
Alzheimer's disease peptide epitope vaccine reduces insoluble but not soluble/oligomeric Abeta species in amyloid precursor protein transgenic mice. J Neurosci (2007) 1.31
Age-dependent sexual dimorphism in cognition and stress response in the 3xTg-AD mice. Neurobiol Dis (2007) 1.30
Anti-A beta 1-11 antibody binds to different beta-amyloid species, inhibits fibril formation, and disaggregates preformed fibrils but not the most toxic oligomers. J Biol Chem (2007) 1.30
Enhanced neuronal excitability in the absence of neurodegeneration induces cerebellar ataxia. J Clin Invest (2004) 1.29
Mifepristone alters amyloid precursor protein processing to preclude amyloid beta and also reduces tau pathology. Biol Psychiatry (2013) 1.28
Phagocytosis of amyloid-beta and inflammation: two faces of innate immunity in Alzheimer's disease. J Alzheimers Dis (2007) 1.28
Classification of the thoroughness of mediastinal staging of lung cancer. Chest (2010) 1.27
Intraneuronal beta-amyloid accumulation in the amygdala enhances fear and anxiety in Alzheimer's disease transgenic mice. Biol Psychiatry (2009) 1.25
Intranasal NAP administration reduces accumulation of amyloid peptide and tau hyperphosphorylation in a transgenic mouse model of Alzheimer's disease at early pathological stage. J Mol Neurosci (2007) 1.24
ACAT1 gene ablation increases 24(S)-hydroxycholesterol content in the brain and ameliorates amyloid pathology in mice with AD. Proc Natl Acad Sci U S A (2010) 1.23
Genetically augmenting tau levels does not modulate the onset or progression of Abeta pathology in transgenic mice. J Neurochem (2007) 1.22
Learning decreases A beta*56 and tau pathology and ameliorates behavioral decline in 3xTg-AD mice. J Neurosci (2007) 1.22
Androgens regulate the development of neuropathology in a triple transgenic mouse model of Alzheimer's disease. J Neurosci (2006) 1.21
Lithium reduces tau phosphorylation but not A beta or working memory deficits in a transgenic model with both plaques and tangles. Am J Pathol (2007) 1.21
Memantine improves cognition and reduces Alzheimer's-like neuropathology in transgenic mice. Am J Pathol (2009) 1.19
Presenilin is necessary for efficient proteolysis through the autophagy-lysosome system in a γ-secretase-independent manner. J Neurosci (2011) 1.18
Multiple events lead to dendritic spine loss in triple transgenic Alzheimer's disease mice. PLoS One (2010) 1.17
A transgenic Alzheimer rat with plaques, tau pathology, behavioral impairment, oligomeric aβ, and frank neuronal loss. J Neurosci (2013) 1.17
Ca2+ signaling in mouse cortical neurons studied by two-photon imaging and photoreleased inositol triphosphate. J Neurosci (2003) 1.17
A two-year study with fibrillar beta-amyloid (Abeta) immunization in aged canines: effects on cognitive function and brain Abeta. J Neurosci (2008) 1.15
Deletion of Abca7 increases cerebral amyloid-β accumulation in the J20 mouse model of Alzheimer's disease. J Neurosci (2013) 1.14
Enhanced ryanodine-mediated calcium release in mutant PS1-expressing Alzheimer's mouse models. Ann N Y Acad Sci (2007) 1.13
Generation and characterization of the humoral immune response to DNA immunization with a chimeric beta-amyloid-interleukin-4 minigene. Eur J Immunol (2003) 1.12
The role of nicotinic acetylcholine receptors in Alzheimer's disease. J Physiol Paris (2006) 1.11
Inclusion body myositis-like phenotype induced by transgenic overexpression of beta APP in skeletal muscle. Proc Natl Acad Sci U S A (2002) 1.11